



## Pharmacological Targets for Neuroinflammation

Guest Editor:

**Dr. Xian (Phoebe) Zhou**

NICM Health Research Institute,  
Western Sydney University,  
Westmead, NSW 2145, Australia

Deadline for manuscript  
submissions:

**closed (31 July 2024)**

### Message from the Guest Editor

Neuroinflammation is the process of inflammation that occurs in the brain or central nervous system and is believed to play a critical role in various neurological disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. This complex process involves several key players, including microglia, astrocytes, pro-inflammatory cytokines (e.g., interleukin-1 $\beta$ , tumor necrosis factor-alpha), and other immune mediators.

The focus of this Special Issue is to gather new breakthrough research findings on various pharmacological targets that have been identified to modulate neuroinflammation and explore their possible crosstalk. We welcome preclinical and clinical studies that investigate novel approaches or potential combination therapies to enhance the efficacy of pharmacological interventions in reducing neuroinflammation and associated neuroinflammatory diseases. In addition, carefully targeted reviews addressing the challenges faced in developing therapeutic agents that specifically target neuroinflammation without interfering with essential immune responses in the brain would also be highly valuable.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)